BioRestorative Therapies, Inc. Annual Report: A Year in Review

I’ve put together this guide to help you understand how BioRestorative Therapies performed this year. My goal is to translate complex filings into plain English so you can decide if this company fits your investment goals.

1. What does the company do?

BioRestorative Therapies is a biotech company focused on regenerative medicine. They use adult stem cells to treat chronic conditions.

2025 was a year of clinical progress. Their lead program, BRTX-100, treats chronic lower back disc disease using a patient’s own stem cells. The FDA granted it "Fast Track" status. Early data from a 36-patient trial looks promising: over 74% of patients saw better physical function, and 72% reported significantly less pain after one year. Importantly, there were no serious safety issues, which is a great sign for future trials.

2. Financial performance

Because the company is still developing its treatments, it isn't making money yet. For the year ending December 31, 2025, the company lost about $12.4 million. Most of this—$8.2 million—went toward research and development.

The company is currently "burning cash" to pay for clinical trials and lab work. To cover these costs, they sell more shares of stock. This creates "dilution," which means your ownership percentage in the company shrinks every time they issue new shares.

3. Major wins and challenges

The biggest win this year was the positive clinical data, which proves their concept works. They also strengthened their patent portfolio in the U.S., Europe, and Israel for ThermoStem. This program uses stem cells to help treat metabolic issues like obesity and diabetes.

The main challenge is the constant need for cash. While the board approved a $2 million stock buyback program in June 2025, they haven't used it. With only $4.8 million in the bank at year-end, they are prioritizing trial costs over returning money to shareholders.

4. Financial health

The company relies entirely on outside funding. They make very little money—less than $100,000 a year—from a legacy skincare line. As of early 2026, they have agreements to sell stock periodically to keep the lights on. Investors should watch their "cash runway," which is currently only 6 to 9 months. They will need to raise more money or find a partner soon to keep operating.

5. Key risks

The biggest risk is extreme dilution. The company has significantly increased the number of shares over the last two years. This can keep the stock price low, even when the company shares good news.

Biotech is also a high-stakes game. If the FDA demands more expensive trials or denies approval for BRTX-100, the company’s main asset could lose its value. Finally, the company relies heavily on a small team of specialized scientists and leaders.

6. Future outlook

The company is pushing to move BRTX-100 into large-scale Phase 3 trials. This will be much more expensive than previous phases. Expect the company to keep selling shares to raise money until they land a big pharmaceutical partner or reach the market.

---

Final Thought for Investors: BioRestorative is in a classic "all-or-nothing" biotech position. The clinical data for BRTX-100 is encouraging, but the company’s survival depends on its ability to secure funding or a partner before its cash runs out. If you are considering an investment, weigh the potential of their regenerative medicine technology against the high likelihood of further share dilution and the company's limited financial cushion.